These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21732539)

  • 1. [³H]UR-MK136: a highly potent and selective radioligand for neuropeptide Y Y₁ receptors.
    Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2011 Sep; 6(9):1566-71. PubMed ID: 21732539
    [No Abstract]   [Full Text] [Related]  

  • 2. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
    Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
    Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of ligand binding modes at the neuropeptide Y Y
    Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
    Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
    Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226.
    Entzeroth M; Braunger H; Eberlein W; Engel W; Rudolf K; Wienen W; Wieland HA; Willim KD; Doods HN
    Eur J Pharmacol; 1995 May; 278(3):239-42. PubMed ID: 7589160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
    Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
    Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
    ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
    Keller M; Teng S; Bernhardt G; Buschauer A
    ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
    Weiss S; Keller M; Bernhardt G; Buschauer A; König B
    Bioorg Med Chem; 2008 Nov; 16(22):9858-66. PubMed ID: 18851917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
    Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
    J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.
    Weiss S; Keller M; Bernhardt G; Buschauer A; König B
    Bioorg Med Chem; 2010 Sep; 18(17):6292-304. PubMed ID: 20688523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
    Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto L; Emmons A; Holmes IP; Montanari D; Norris R; Walters DJ; Watson SP
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4022-5. PubMed ID: 19581086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.
    Hipskind PA; Lobb KL; Nixon JA; Britton TC; Bruns RF; Catlow J; Dieckman-McGinty DK; Gackenheimer SL; Gitter BD; Iyengar S; Schober DA; Simmons RM; Swanson S; Zarrinmayeh H; Zimmerman DM; Gehlert DR
    J Med Chem; 1997 Nov; 40(23):3712-4. PubMed ID: 9371234
    [No Abstract]   [Full Text] [Related]  

  • 15. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
    Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
    Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
    Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
    J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
    Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
    J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
    Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.